Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial
- 주제(키워드) Lactobacillus gasseri BNR17 , Irritable bowel syndrome , Probiotics
- 주제(기타) Food Science & Technology
- 설명문(일반) [Kim, Ji Yeon] Seoul Natl Univ Sci & Technol, Dept Food Sci & Technol, Seoul 01811, South Korea; [Park, Yeo Jin; Lee, Hyo Jin; Park, Min Young; Kwon, Oran] Ewha Womans Univ, Dept Nutr Sci & Food Management, Seoul 03760, South Korea
- 등재 SCIE, SCOPUS, KCI등재
- 발행기관 KOREAN SOCIETY FOOD SCIENCE & TECHNOLOGY-KOSFOST
- 발행년도 2018
- URI http://www.dcollection.net/handler/ewha/000000151656
- 본문언어 영어
- Published As http://dx.doi.org/10.1007/s10068-017-0296-7
- 저작권 이화여자대학교 논문은 저작권에 의해 보호받습니다.
초록/요약
Lactobacillus gasseri BNR17 is a strain isolated from human breast milk. The objective of this randomized, double-blind, placebo-controlled, and preliminary dose-finding trial was to find the effective dose and evaluate the effect of Lb. gasseri BNR17 on irritable bowel syndrome (IBS) symptoms. A total of 55 volunteers aged over 20 years with body mass index over 23 kg/m(2) were randomized to intake a placebo, low-dose (BNR-L, 2 x 10(8) CFU/day), intermediate-dose (BNR-M, 2 x 10(9) CFU/day), or high-dose BNR (BNR-H, 2 x 5 x 10(9) CFU/day) for four weeks. Questionnaire for IBS symptoms scores and Lb. gasseri BNR17 in feces were assessed at the beginning and end of the trial. Among IBS symptoms scores, abdominal pain score was significantly reduced in BNR-H group. Lb. gasseri BNR17 was detected in all intake groups except placebo. In the preliminary study, Lb. gasseri BNR17 was confirmed to have probiotic properties.
more